Medication and specific populations

Factors including insulin use and ethnicity can help predict who will develop proliferative diabetic retinopathy within 5 years after type 2 diabetes diagnosis, say researchers.

Using a linear insulin to carbohydrate ratio to determine breakfast insulin requirements leads to significant differences in time in glycemic range and hypoglycemia rates when meal carbohydrate quantities vary, shows a study in children and young adults.

Analysis of older people living in Denmark shows that doctors are increasingly deprescribing medications given solely to reduce blood glucose as people with type 2 diabetes near their end of life.

Click through for more information on this expanded indication

Reasons for ethnic disparities in statin prescribing in UK residents with type 2 diabetes are not clear, but may result in preventable atherosclerotic cardiovascular disease events, research suggests.

The Omnipod 5 tubeless automated insulin delivery system improves glycemic outcomes of very young children with type 1 diabetes and the sleep of their caregivers, report researchers.

Dasiglucagon, a next-generation glucagon analog in a ready-to-use formulation, rapidly restores plasma glucose levels following severe hypoglycemia in children and adolescents with type 1 diabetes, show findings from a phase 3 trial.

Older people with type 2 diabetes are more likely to receive inappropriately intensive glucose-lowering treatment if they live in high- versus middle income countries, show data from the global DISCOVER study.

Results from a US retrospective study suggest that usage rates of SGLT2 inhibitors remain low in people with type 2 diabetes, particularly among Black and Asian individuals, women, and lower-income groups.

Black West African men have lower levels of insulin secretion in response to a meal than their White Northern European counterparts, irrespective of insulin sensitivity, study findings indicate.

Older people with type 2 diabetes who initiate treatment with long-acting insulin analogs have a lower risk for severe hypoglycemia than those using neutral protamine Hagedorn insulin, real-world study findings suggest.

Click through to read more on this announcement

Analysis of older participants in the BRIGHT trial suggests that this subgroup may do slightly better with insulin glargine-300 than with degludec.

Findings from a meta-analysis indicate that Asian people may derive greater cardiovascular benefit from SGLT2 inhibitors and glucagon-like peptide-1 receptor agonists than their White counterparts.

Older individuals with type 2 diabetes and low glycated hemoglobin receiving treatment with a sulfonylurea or insulin have an increased risk for severe hypoglycemia, but there is no clear indication of an increased mortality risk, suggest UK study results.

Researchers find that older adults with diabetes are frequently treated to an intensive glycemic target, putting them at risk for poor outcomes, particularly when high-risk agents are used.

SGLT2 inhibitors are associated with lower rates of heart failure hospitalization, all-cause mortality, and hypoglycemia, but higher rates of diabetic ketoacidosis, when compared with DPP-4 inhibitors in older adults with type 2 diabetes, suggests a Canadian study.

Click through to read more on this announcement

Cardiovascular event rates do not differ significantly among people with type 2 diabetes treated with linagliptin or glimepiride regardless of age, but those who receive linagliptin have lower risks for falls and hypoglycemia, CAROLINA trial data show.

Results from an observational study suggest that the use of metformin in older patients with type 2 diabetes is associated with a reduced decline in both global cognition and executive function, and a decreased risk for dementia.